Cerba HealthCare, a leading player in medical diagnosis, is providing the medical community and patients with a new quantitative serology test for SARS CoV 2. This new clinical tool helps measure the strength of an individual’s immune response, both during SARS-CoV-2 infection and also after COVID-19 vaccination.

The antibodies measured by this test identify a specific site of the famous S-protein (spike or spicule) that is present on the surface of SARS-CoV-2, enabling the virus to attach to respiratory cells. This protein is the target of the vast majority of vaccines available today.

This quantitative and global measurement test for anti-protein S antibodies is not altered by the different variants. It therefore gives a better picture of patients’ immune status, providing an individual and collective perspective on the level of protection.

"Older techniques, including so-called rapid testing, did not give this overall assessment of post-vaccine and post-infectious immunity, and the scientific community has not yet established the level of protective antibodies after vaccination," said Dr. Michel Sala, Medical Director of Cerballiance. "This new test is therefore the first key step towards better understanding patients’ acquired immunity, from a clinical, medical and also epidemiological perspective."

For France, this new test is available for the medical community and patients across the entire Cerballiance national network. It requires a simple blood sample, with results available within 24 hours.